AbbVie Stock News

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work.

I present you our framework for buying and selling dividend stocks. It follows our simple motto of buy low, sell high, get paid to wait. Here are 2 brilliant buys and 2 smart sells for Q2 2024.

The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April. As I've mentioned many times before, techn

The latest trading day saw AbbVie (ABBV) settling at $180.76, representing a -0.74% change from its previous close.

10 Dividend Growth Stocks: March 2024

Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manuf

AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of nove

AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.

AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.

Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tier

The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments conside